i-SENS, Inc. (099190.KQ)
KRW 15420.0
(1.65%)
KRW 15420.0
(1.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 91.12 Billion KRW | 10.92% |
| 2022 | 82.15 Billion KRW | 25.89% |
| 2021 | 65.26 Billion KRW | 6.26% |
| 2020 | 61.42 Billion KRW | 14.93% |
| 2019 | 53.44 Billion KRW | 11.17% |
| 2018 | 48.06 Billion KRW | 9.81% |
| 2017 | 43.77 Billion KRW | 27.51% |
| 2016 | 34.33 Billion KRW | 40.75% |
| 2015 | 24.39 Billion KRW | 6.35% |
| 2014 | 22.93 Billion KRW | 76.84% |
| 2013 | 12.96 Billion KRW | 8.1% |
| 2012 | 11.99 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 66.51 Billion KRW | -61.67% |
| 2024 Q1 | 67.94 Billion KRW | 167.01% |
| 2024 Q2 | 67.93 Billion KRW | -0.03% |
| 2023 Q2 | 19.19 Billion KRW | -1.13% |
| 2023 FY | 91.12 Billion KRW | 10.92% |
| 2023 Q1 | 19.4 Billion KRW | -19.44% |
| 2023 Q3 | 26.1 Billion KRW | 36.04% |
| 2023 Q4 | 25.44 Billion KRW | -2.52% |
| 2022 Q2 | 17.97 Billion KRW | -3.5% |
| 2022 Q1 | 18.62 Billion KRW | 5.37% |
| 2022 FY | 82.15 Billion KRW | 25.89% |
| 2022 Q4 | 24.09 Billion KRW | 13.95% |
| 2022 Q3 | 21.14 Billion KRW | 17.67% |
| 2021 FY | 65.26 Billion KRW | 6.26% |
| 2021 Q2 | 15.76 Billion KRW | 7.95% |
| 2021 Q3 | 17.31 Billion KRW | 9.81% |
| 2021 Q1 | 14.6 Billion KRW | -14.22% |
| 2021 Q4 | 17.67 Billion KRW | 2.09% |
| 2020 Q3 | 14.31 Billion KRW | -8.75% |
| 2020 FY | 61.42 Billion KRW | 14.93% |
| 2020 Q4 | 17.02 Billion KRW | 18.91% |
| 2020 Q2 | 15.68 Billion KRW | 12.23% |
| 2020 Q1 | 13.97 Billion KRW | -39.57% |
| 2019 FY | 53.44 Billion KRW | 11.17% |
| 2019 Q4 | 23.13 Billion KRW | 93.04% |
| 2019 Q3 | 11.98 Billion KRW | 40.25% |
| 2019 Q2 | 8.54 Billion KRW | -32.74% |
| 2019 Q1 | 12.7 Billion KRW | 7.99% |
| 2018 Q3 | 12.68 Billion KRW | -4.64% |
| 2018 FY | 48.06 Billion KRW | 9.81% |
| 2018 Q2 | 13.29 Billion KRW | 4.21% |
| 2018 Q1 | 12.76 Billion KRW | -6.1% |
| 2018 Q4 | 11.76 Billion KRW | -7.24% |
| 2017 Q2 | 10.41 Billion KRW | -19.4% |
| 2017 FY | 43.77 Billion KRW | 27.51% |
| 2017 Q1 | 12.92 Billion KRW | 29.77% |
| 2017 Q3 | 11.72 Billion KRW | 12.56% |
| 2017 Q4 | 13.58 Billion KRW | 15.89% |
| 2016 FY | 34.33 Billion KRW | 40.75% |
| 2016 Q2 | 10.56 Billion KRW | 24.21% |
| 2016 Q1 | 8.5 Billion KRW | 65.72% |
| 2016 Q3 | 9.64 Billion KRW | -8.64% |
| 2016 Q4 | 9.95 Billion KRW | 3.22% |
| 2015 Q1 | 6.01 Billion KRW | -9.82% |
| 2015 Q4 | 5.13 Billion KRW | -38.9% |
| 2015 Q2 | 6.58 Billion KRW | 9.55% |
| 2015 Q3 | 8.39 Billion KRW | 27.5% |
| 2015 FY | 24.39 Billion KRW | 6.35% |
| 2014 Q3 | 5.82 Billion KRW | 8.08% |
| 2014 FY | 22.93 Billion KRW | 76.84% |
| 2014 Q1 | 5.05 Billion KRW | 82.75% |
| 2014 Q4 | 6.66 Billion KRW | 14.42% |
| 2014 Q2 | 5.39 Billion KRW | 6.69% |
| 2013 Q1 | 3.43 Billion KRW | 55.46% |
| 2013 Q2 | 4.13 Billion KRW | 20.52% |
| 2013 FY | 12.96 Billion KRW | 8.1% |
| 2013 Q3 | 2.63 Billion KRW | -36.46% |
| 2013 Q4 | 2.76 Billion KRW | 5.12% |
| 2012 Q3 | 2.86 Billion KRW | 0.0% |
| 2012 Q4 | 2.2 Billion KRW | -22.81% |
| 2012 FY | 11.99 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 78.35 Billion KRW | -16.298% |
| InBody Co.,Ltd | 87.36 Billion KRW | -4.308% |
| Curexo Inc. | 18.16 Billion KRW | -401.727% |
| Seegene, Inc. | 210.08 Billion KRW | 56.622% |
| Ray Co., Ltd. | 59.03 Billion KRW | -54.372% |
| Gencurix Inc. | 12.79 Billion KRW | -612.051% |
| Sugentech Inc. | 18.6 Billion KRW | -389.849% |
| L&C Bio Co., Ltd | 25.86 Billion KRW | -252.384% |